16/02/2026
What a wonderful woman and scientist.
In 1937, a nineteen year old woman graduated summa cm laude in chemistry. She applied to fifteen graduate schools. Not one offered her funding. She was told laboratories did not hire women. She never earned a PhD. She later received the Nobel Prize and helped save millions of lives.
Her name was Gertrude Belle Elion, and history nearly overlooked her.
She was born on January 23, 1918, in New York City, to Jewish immigrant parents. Her father, Robert, had come from Lithuania at twelve and worked his way through dental school. Her mother, Bertha, arrived from what is now Poland at fourteen. They lived in a modest apartment connected to her father’s dental office in Manhattan. When Gertrude was six, her brother Herbert was born, and the family moved to the Bronx.
She was a remarkable student from the start. She skipped two grades and graduated from Walton High School at fifteen. She loved learning with what she later described as an insatiable appetite, excelling in every subject and asking questions about everything.
Then, in the summer of 1933, her life shifted.
Her grandfather, the person she had been closest to since early childhood, was dying of stomach cancer. She watched him endure months of suffering. She watched doctors try and fail. She watched illness take someone she loved, and she could do nothing to stop it.
She later said she had no particular interest in science until her grandfather’s death. After that, she decided no one should have to suffer so much.
That autumn, at fifteen, she enrolled at Hunter College, the free women’s college of the City University of New York. Her family’s savings had been wiped out in the 1929 market crash, and free tuition made her education possible. She chose chemistry with a clear goal in mind: to help cure cancer.
She graduated in 1937 at nineteen, summa cm laude and Phi Beta Kappa. She was gifted, focused, and ready to continue.
The world, however, was not prepared to welcome her.
The Great Depression had left few jobs available, and the laboratory positions that did exist were largely closed to women. She applied to fifteen graduate programs seeking financial support. None offered it.
She spent time in secretarial school. She accepted a short term position teaching biochemistry at the New York Hospital School of Nursing. When that ended, she found herself unemployed again. Rather than wait, she took an unpaid laboratory assistant role to gain experience. After a year and a half, she was earning twenty dollars a week.
Still, she kept studying.
In 1939, she began graduate work in chemistry at New York University, attending classes at night while teaching high school science during the day. She was the only woman in her courses. In 1941, she earned her Master of Science degree.
She later reflected that World War II, which created a shortage of male chemists, allowed opportunities to open slightly. Doors that had been shut to women cracked open because so many men were away.
In 1944, she joined Burroughs Wellcome as a laboratory assistant to biochemist George Hitchings. That decision changed her life.
Hitchings recognized what others had failed to see. She was not merely competent. She was exceptional.
Together, they pursued a new approach to drug development known as rational drug design.
At the time, many medications were discovered through trial and error. Hitchings and Elion instead studied the biochemistry of disease at the molecular level. They analyzed how cells reproduced and then created compounds designed to target differences between healthy and diseased cells. They aimed for precision rather than chance.
While working full days in the laboratory, she also pursued doctoral studies at Brooklyn Polytechnic Institute, commuting long distances for night classes. In 1946, she was told she could no longer continue part time and would have to leave her job to complete her doctorate.
It was a painful choice. She chose to remain with her research. She never earned the PhD.
Then came the breakthroughs.
In 1950 and 1951, she synthesized compounds including 6-mercaptopurine, or 6-MP, the first drug shown to effectively treat childhood leukemia. Before 6-MP, a diagnosis of childhood leukemia almost always led to death within months.
While 6-MP alone brought temporary remission, combined therapies began producing lasting survival. Children who once faced certain death began living longer, then growing up.
She went on to help develop azathioprine, the first immunosuppressant that made organ transplantation viable. Previously, transplanted organs were rejected by the immune system. Azathioprine allowed that response to be controlled, making kidney and heart transplants possible and extending countless lives.
In the 1970s, her team developed acyclovir, one of the first effective antiviral drugs. It demonstrated that viruses could be targeted with specificity, changing treatment for infections such as herpes simplex, Epstein-Barr virus, chicken pox, and shingles.
Her earlier research on DNA and RNA interactions also contributed to the development of AZT, the first effective treatment for HIV and AIDS. Even after retirement, she played a role in that effort during the height of the AIDS crisis.
Amid these achievements, she carried private loss. Before joining Burroughs Wellcome, she had become engaged to Leonard Canter. He developed subacute bacterial endocarditis, an infection then without treatment, and died.
She never married. She later said no one could match what she had lost. She devoted herself to her work and to her extended family, becoming beloved by her brother’s children and grandchildren.
In 1967, she became head of the Department of Experimental Therapy at Burroughs Wellcome, serving until her retirement in 1983. Retirement did not slow her. She continued as Scientist Emeritus and Consultant and became a Research Professor at Duke University, mentoring medical students and publishing papers alongside them.
In 1988, the Nobel Prize in Physiology or Medicine was awarded to Gertrude B. Elion and two colleagues for their discoveries of principles that transformed drug treatment.
She was seventy. She had spent more than forty years in research. She was among the few science laureates who had never earned a doctorate. Brooklyn Polytechnic later awarded her an honorary PhD.
In 1991, she became the first woman inducted into the National Inventors Hall of Fame. President George H.W. Bush presented her with the National Medal of Science. Universities across the country granted her honorary doctorates in recognition of achievements that exceeded conventional credentials.
She continued mentoring young scientists, especially women, speaking openly about discrimination and encouraging change. She served on advisory boards for major medical and global health organizations and held more than forty five patents.
Gertrude Belle Elion died on February 21, 1999, at eighty one.
By then, her medications had saved millions. Children with leukemia reached adulthood. Transplant recipients lived years they would never have had. Patients with viral infections recovered. Those living with HIV benefited from treatments built on her work.
Her influence extends beyond specific drugs. She helped shift medicine from guesswork to targeted design. Modern cancer therapies, antiviral drugs, and molecularly precise treatments trace part of their lineage to the methods she and Hitchings developed.
She once said it is remarkable how much can be accomplished when credit does not matter.
Gertrude Elion deserves to be remembered alongside the most celebrated figures in medical history.
She was the young woman who vowed to fight cancer after watching her grandfather suffer. The scientist turned away by fifteen universities. The researcher who chose her laboratory over a doctoral title and changed medicine regardless. The innovator whose brilliance reshaped science, even without the credentials others said were essential.
